Inside the research
STAAR Surgical Company
STAA Research profile · latest available data
Price overview
$20.51
▲ +1.43 (+7.5%)
| 52w hi | $33.34 |
|---|---|
| 52w lo | $16.10 |
| Vol | 1.31M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.10
| Short | -0.38 |
|---|---|
| Medium | -0.02 |
| Long | +0.31 |
computed 2026-09-27
Key fundamentals
STAAR Surgical Company
Healthcare · Medical Instruments & Supplies
| Market cap | $1.03B |
|---|---|
| Enterprise value | $882.91M |
| Trailing P/E | 256.38x |
| Forward P/E | 20.03x |
| EV / EBITDA | 17.74x |
| P / S (ttm) | 3.03x |
| Profit margin | 1.1% |
| Return on equity | 1.1% |
| Revenue growth | +111.0% |
| Debt / equity | 9.84 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.31 | |
| Sector | +0.08 | |
| Technical | -0.29 | |
| Earnings | +0.00 | |
| Sentiment | +0.08 |
macro × 1.00 · 2026-09-27
Business overview
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Risk Metrics
| Beta vs SPX | 0.63 |
|---|---|
| Corr SPX | 0.16 |
| Annual vol | 64.4% |
| Annual ret | +0.0% |
| Sharpe | 0.00 |
| Max DD | -59.5% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-12 | Earnings Release, Reg FD Disclosure… | read |
| 2026-08-06 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-22 | Officer / Director Change, Shareholder Vote… | read |
| 2026-06-09 | Officer / Director Change | read |
| 2026-05-13 | Earnings Release, Reg FD Disclosure… | read |
| 2026-04-08 | Reg FD Disclosure, Exhibits | read |
| 2026-03-03 | Earnings Release, Reg FD Disclosure | read |
| 2026-02-05 | Officer / Director Change | read |
| 2026-02-02 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-01-16 | Officer / Director Change | read |
| 2026-01-15 | Material Agreement, Listing Notice… | read |
| 2026-01-06 | Termination of Agreement, Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Foust Warren | Officer, President and CE | Option exercise | 20.79K | — |
| 2026-07-31 | Foust Warren | Officer, President and CE | Withheld for tax | 10.58K | $257.63K |
| 2026-07-31 | ANDREWS DEBORAH J | Officer, Chief Financial | Option exercise | 20.79K | — |
| 2026-07-31 | ANDREWS DEBORAH J | Officer, Chief Financial | Withheld for tax | 10.58K | $257.63K |
| 2026-06-25 | ANDREWS DEBORAH J | Officer, Chief Financial | Option exercise | 13.96K | — |
| 2026-06-25 | ANDREWS DEBORAH J | Officer, Chief Financial | Withheld for tax | 6.48K | $202.24K |
| 2026-06-18 | SILVERMAN LOU | Director | Option exercise | 10.68K | — |
| 2026-06-18 | Jiang Wei | Director | Option exercise | 10.68K | — |
| 2026-06-18 | Butcher Arthur C | Director | Option exercise | 5.34K | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.6% |
| HHI | 4,058 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $50.76M | 1.77M |
| Citadel Advisors | $12.42M | 432.78K |
| Capital Research / Capital World | $11.60M | 404.18K |
| Renaissance Technologies | $9.77M | 340.40K |
| Fidelity / FMR LLC | $505.62K | 17.62K |
| AQR Capital Management | $374.32K | 13.05K |
| T. Rowe Price Group | $1.73K | 60.17K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $239.44M | +10.0% | |
| Gross profit | $252.65M | +13.6% | |
| Operating income | -$91.71M | +39.1% | |
| Net income | $21.35M | +41.2% | |
| Cash from ops | $15.72M | +23.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $19.91 | $20.80 | $19.70 | $20.51 | 1.31M |
| Sep 24 | $19.80 | $20.08 | $19.05 | $19.08 | 880.10K |
| Sep 23 | $20.66 | $21.00 | $19.65 | $19.80 | 845.90K |
| Sep 22 | $20.40 | $21.03 | $20.14 | $20.65 | 751.10K |
| Sep 21 | $21.00 | $21.03 | $20.18 | $20.32 | 768.00K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →